Business
Viking Therapeutics to Present Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek 2021
Poster Presentations to Highlight Data From the Company's Multi-Receptor Agonists in a Rodent Model of Obesity SAN DIEGO, Oct. 25, 2021 /PRNewswire/ -- Viking
About this update from Viking Therapeutics, Inc.
[{"type":"text","content":"Poster Presentations to Highlight Data From the Company's Multi-Receptor Agonists in a Rodent Model of Obesity\n\n\nSAN DIEGO, Oct. 25, 2021 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that preclinical data from a series of novel dual agonists of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors will be presented at ObesityWeek 2021, the annual meeting of The Obesity Society. Results from studies in diet induced obese (DIO) mice will be featured in two poster presentations at the conference, which is being held virtually November 1-5, 2021.\n\n \n \n \n \n \n \n\n \nDetails of the poster presentations are as follows:\nPoster Presentation #206:\nTitle: Novel Co-agonists of GLP-1 and GIP Receptors Produce Robust Weight Loss in a Rodent Model of Obesity Presenting Author: Kader Yagiz, Ph.D., Associate Director, Pharmacology, Viking Therapeutics Conference Track: Metabolism and Integrative PhysiologyPoster Presentation #207:\nTitle: Novel Dual Incretin Receptor Agonists Reduce Body Weight and Improve Metabolic Profile in DIO Mice Presenting Author: Kader Yagiz, Ph.D., Associate Director, Pharmacology, Viking Therapeutics Conference Track: Metabolism and Integrative PhysiologyThese presentations highlight early results from certain of the company's internal development efforts, and represent an important potential expansion of the company's pipeline of novel therapeutics for the treatment of metabolic and endocrine disorders. Further information will be provided in the coming weeks, including details on the data being presented at ObesityWeek 2021.\nAbout Viking Therapeutics, Inc. \nViking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel, orally available, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metab...